Published in Prostate on August 17, 2010
SOCS proteins in development and disease. Am J Clin Exp Immunol (2013) 1.17
SOCS, inflammation, and cancer. JAKSTAT (2013) 1.13
Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci (2014) 1.05
Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene (2015) 1.03
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 0.95
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocr Relat Cancer (2014) 0.89
Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics (2014) 0.86
TGF-β mediated DNA methylation in prostate cancer. Transl Androl Urol (2012) 0.85
Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion. PLoS One (2012) 0.85
Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis (2011) 0.84
Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol (2014) 0.83
SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. Cancer Immunol Res (2015) 0.83
SOCS3 promotor hypermethylation and STAT3-NF-κB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol (2013) 0.82
The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int (2014) 0.81
Human primary keratinocytes show restricted ability to up-regulate suppressor of cytokine signaling (SOCS)3 protein compared with autologous macrophages. J Biol Chem (2012) 0.80
SOCS3 Methylation Predicts a Poor Prognosis in HBV Infection-Related Hepatocellular Carcinoma. Int J Mol Sci (2015) 0.80
Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J Exp Clin Cancer Res (2016) 0.79
IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol (2016) 0.79
A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients. Biomark Res (2014) 0.78
Longitudinal Study of DNA Methylation of Inflammatory Genes and Cancer Risk. Cancer Epidemiol Biomarkers Prev (2015) 0.78
The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer. Oncotarget (2016) 0.77
Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer. Oncol Rep (2013) 0.76
Regulation of cancer stem cells by RING finger ubiquitin ligases. Stem Cell Investig (2014) 0.76
Epigenetic Signatures at AQP3 and SOCS3 Engage in Low-Grade Inflammation across Different Tissues. PLoS One (2016) 0.75
The prognostic role of BORIS and SOCS3 in human hepatocellular carcinoma. Medicine (Baltimore) (2017) 0.75
Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. J Hematol Oncol (2017) 0.75
Expression array analysis of the hepatocyte growth factor invasive program. Clin Exp Metastasis (2015) 0.75
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochir (Wien) (2012) 1.99
Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int (2006) 1.79
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol (2010) 1.66
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62
Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer (2008) 1.55
Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol (2004) 1.54
Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica (2008) 1.54
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.51
Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer (2003) 1.50
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma (2013) 1.47
Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. AIDS (2010) 1.45
Primary plasma cell leukemia followed by testicular plasmacytoma. Int J Hematol (2011) 1.44
Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer. Anal Quant Cytol Histol (2007) 1.43
Endothelial progenitor cells in HIV-positive patients: what are we talking about? J Acquir Immune Defic Syndr (2013) 1.42
Paraneoplastic syndromes in patients with urological malignancies. Urol Int (2009) 1.36
Advanced bladder cancer: new agents and new approaches. A review. Urol Oncol (2010) 1.28
Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg (2003) 1.24
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res (2009) 1.22
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood (2007) 1.19
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res (2011) 1.18
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemother Pharmacol (2007) 1.16
Role of the life span determinant P66(shcA) in ethanol-induced liver damage. Lab Invest (2008) 1.15
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica (2009) 1.15
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol (2010) 1.12
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol (2007) 1.10
Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol (2002) 1.10
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer (2010) 1.07
Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer (2002) 1.07
Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. J Neurooncol (2009) 1.06
Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma? Cancer Cytopathol (2013) 1.06
Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC? Virchows Arch (2014) 1.06
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood (2011) 1.05
A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica (2008) 1.04
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer (2011) 1.02
Imaging in prostate cancer diagnosis: present role and future perspectives. Urol Int (2011) 1.02
Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol (2010) 1.00
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica (2009) 0.99
Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurol Res (2006) 0.99
Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood (2012) 0.98
Complications of extracorporeal shock wave lithotripsy for urinary stones: to know and to manage them-a review. ScientificWorldJournal (2012) 0.97
Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. J Neurosurg (2006) 0.97
Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol (2009) 0.97
Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia (2011) 0.97
Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer (2008) 0.96
BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol (2012) 0.93
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol (2012) 0.93
The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. Int J Cancer (2012) 0.93
Congenital tumors of the retrorectal space in the adult: report of two cases and review of the literature. Tumori (2008) 0.92
Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. World J Surg Oncol (2008) 0.91
Paediatric Kikuchi-Fujimoto disease: a benign cause of fever and lymphadenopathy. Pediatr Blood Cancer (2008) 0.91
Renal hemangiopericytoma: case report and review of the literature. Urology (2008) 0.91
Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer (2008) 0.89
Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. J Infect (2006) 0.89
Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int (2005) 0.89
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma. Am J Clin Pathol (2012) 0.89
Prediction of 'awakening' and outcome in prolonged acute coma from severe traumatic brain injury: evidence for validity of short latency SEPs. Clin Neurophysiol (2005) 0.88
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res (2009) 0.88